Impact Biomedical, Inc. is a biotechnology company engaged in discovering, developing, and patenting healthcare solutions. It discovers, confirms, and patents science and technologies, which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through research, licensing, co-development, joint ventures, and other relationships. It has several technologies that are in continuing development, which include Linebacker, Laetose, Functional Fragrance Formulation (3F), Equivir/Equivir G, and Celios. Linebacker is a platform of small molecule electrophilically enhanced polyphenol compounds with potential application in oncology (solid tumors), inflammatory disorders, and neurology. Laetose technology is derived from a combination of multiple sugars independently with myo-inositol. 3F is a suite of organic functional fragrances. Celios is an air purification technology. It also evaluates additional technologies.
성장 중
회사는 성장 단계에 있으며, 최신 연간 수익은 미화 32.00K에 달합니다.
고수익 성장
회사의 순이익은 업계 선두를 달리고 있으며, 최근 연간 순이익은 미화 32.00K에 달합니다.
과소 평가된
회사의 최신 PE은 -1.48로, 최근 3년 기준 낮은 백분위 범위에 속합니다.
기관 매수
최신 기관 보유 주식 수는 2.77M주이며, 전 분기 대비 42.98% 증가했습니다.